secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001104659-23-090875
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics Q2 net loss $13.4M; DKN-01 CRC trial advances to Part B
-------------------------------------------------------------------------

- Net loss $13.4M in Q2 2023 vs $17.0M in Q2 2022; R&D expenses fell to $11.1M.
- Cash and equivalents $91.4M at June 30, 2023; interest income $1.2M.
- DeFianCe Part A CRC study achieved >20% ORR; 130-patient randomized Part B initiated.
- DisTinGuish GEA data: 73% ORR (mITT), median OS 19.5 months, median PFS 11.3 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923090875/0001104659-23-090875-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923090875/tm2323558d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-090875

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer